Please assess the completion status of the following clinical trial:

Trial Title: Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of mantle cell lymphoma~* Stable disease after first- or second-line chemotherapy~* No uncontrolled cerebral or leptomeningeal disease~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* Life expectancy ≥ 3 months~* Age ≥ 60 years or patients ≥ 40 and \< 60 years who are not suitable for high-dose chemotherapy followed by autologous stem cell transplantation or allogeneic stem cell transplantation~* ANC ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin \> 9 g/dL~* Serum creatinine ≤ 1.5 times upper limit of normal (ULN)~* SGPT and SGOT ≤ 3 times ULN~* Bilirubin ≤ 1.5 times ULN~* No other malignancies within the past 3 years except treated cervical carcinoma or basal cell cancer~* No other serious or non-controlled illnesses (e.g., diabetes mellitus, uncontrolled hypertension, serious infections, serious malnutrition, unstable angina pectoris, weak heart, myocardial infarction within the past 6 months, chronic liver illness, active ulceration in the gastrointestinal tract, psychiatric illness)~* No known HIV infection~* No gastrointestinal disturbances that could influence the absorption of everolimus and cause short-intestine syndrome (e.g., atrophic gastritis)~* No coagulation or bleeding diatheses~* Not pregnant or nursing~* Fertile patients must use effective contraception~* Patients must have complied with their previous drug prescription~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* See Patient Characteristics~* Recovered from all prior therapy~* At least 2 weeks since prior surgery, radiotherapy, or systemic antitumor therapy~* More than 4 weeks since prior experimental medication~* No chronic therapy with systemic steroids or other immunosuppressants except rituximab~* No prior organ transplantation~* No therapy with vitamin K antagonist, except low-dose coumarin~* No prior mTOR inhibitors

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).